Javed Butler, MBBS, FACC

General Statement of Disclosure:

CONSULTING FEES/HONORARIA: Bayer(SIGNIFICANT), Relypsa(SIGNIFICANT), Boehringer Ingelheim Pharmaceuticals, Inc(SIGNIFICANT), Merck & Co., Inc.(SIGNIFICANT), Novartis(SIGNIFICANT), Medtronics(MODEST), Luitpold Pharmaceuticals, Inc(MODEST), AstraZeneca Pharmaceuticals(MODEST), Janssen(SIGNIFICANT), Roche(MODEST), Vifor(SIGNIFICANT), Berlin Cures(MODEST), Adrenomed(MODEST), Array(MODEST), Innolife(MODEST), SC Pharma(MODEST), LivaNova(MODEST), Arena Pharma(MODEST), Novo Nordisk Inc.(MODEST), FIRE1(NONE), Impulse Dynamics(MODEST), Abbott Laboratories(MODEST), Eli Lilly and Company(SIGNIFICANT), V Wave Limited(MODEST), Corvia(MODEST), Myocardia(MODEST), CVRx(SIGNIFICANT), Baxter International Inc(MODEST), Gilead Sciences, Inc. (MODEST) SPEAKER'S BUREAU: Novartis Corporation(SIGNIFICANT), Janssen Pharmaceuticals, Inc(SIGNIFICANT) OTHER FINANCIAL BENEFIT: Medscape(SIGNIFICANT), G3 Pharmaceutical(NONE)

View Full Disclosure